{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:53:35Z","timestamp":1781560415511,"version":"3.54.5"},"reference-count":49,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T00:00:00Z","timestamp":1443744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Interferon &amp; Cytokine Research"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>\n                    The omental fat band (OFB) is the predominant site for metastatic seeding of ovarian cancer. Previously, we highlighted the influx and accumulation of neutrophils and macrophages in the OFB following syngeneic ovarian cancer cell seeding as an important factor in the development of a protumorigenic cascade. Here we investigated localized immunomodulation as a means of promoting a successful protective response. As an important T\n                    <jats:sub>H<\/jats:sub>\n                    1-type immunomodulator, interleukin (IL)-12 has previously been investigated clinically as an anticancer therapeutic. However, systemic IL-12 administration was associated with serious side effects, galvanizing the development of immune or accessory cells engineered to express secreted or membrane-bound IL-12 (mbIL-12). Using an mbIL-12-expressing cell variant, we demonstrate that localized IL-12 in the tumor microenvironment significantly delays disease development. The mbIL-12-mediated decrease in tumor burden was associated with a significant reduction in neutrophil and macrophage infiltration in the OFB, and correlated with a reduced expression of neutrophil and macrophage chemoattractants (CXCL1, -2, -3 and CCL2, -7). Vaccination with mitotically impaired tumor cells did not confer protection against subsequent tumor challenge, indicating that IL-12 did not impact the immunogenicity of the cancer cells. Our findings are in agreement with previous reports suggesting that IL-12 may hold promise when delivered in a targeted and sustained manner to the omental microenvironment. Furthermore, resident cells within the omental microenvironment may provide a reservoir that can be activated and mobilized to prevent metastatic seeding within the peritoneum and, therefore, may be targets for chemotherapeutics.\n                  <\/jats:p>","DOI":"10.1089\/jir.2015.0049","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T11:23:58Z","timestamp":1443785038000},"page":"62-73","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer"],"prefix":"10.1177","volume":"36","author":[{"given":"Courtney A.","family":"Cohen","sequence":"first","affiliation":[{"name":"Virginia Polytechnic Institute and State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Shea","sequence":"additional","affiliation":[{"name":"Virginia Polytechnic Institute and State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lynn","family":"Heffron","sequence":"additional","affiliation":[{"name":"Virginia Polytechnic Institute and State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Schmelz","sequence":"additional","affiliation":[{"name":"Virginia Polytechnic Institute and State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Virginia Polytechnic Institute and State University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,10,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.6595"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.08.028"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1245"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.159"},{"issue":"3","key":"e_1_3_3_6_1","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","unstructured":"Atkins MB, , Robertson MJ, , Gordon M, , Lotze MT, , DeCoste M, , DuBois JS, , Ritz J, , Sandler AB, , Edington HD, , Garzone PD, , Mier JW, , Canning CM, , Battiato L, , Tahara H, , Sherman ML. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res, 3(3):409\u2013417.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_3_7_1","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta E","year":"1998","unstructured":"Bajetta E, , Del Vecchio M, , Mortarini R, , Nadeau R, , Rakhit A, , Rimassa L, , Fowst C, , Borri A, , Anichini A, , Parmiani G. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res, 4(1):75\u201385.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066477"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0227"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(01)00032-6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017676"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021910"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0776"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.051222"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915000107"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043196"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.30.19060"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e31824b4611"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01864.x"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(99)01547-9"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58814"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2012.0119"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-012-9371-y"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050522"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(95)00096-S"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1523-1"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-66"},{"issue":"12","key":"e_1_3_3_28_1","first-page":"3686","article-title":"Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma","volume":"8","author":"Lenzi R","year":"2002","unstructured":"Lenzi R, , Rosenblum M, , Verschraegen C, , Kudelka AP, , Kavanagh JJ, , Hicks ME, , Lang EA, , Nash MA, , Levy LB, , Garcia ME, , Platsoucas CD, , Abbruzzese JL, , Freedman RS. 2002. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res, 8(12):3686\u20133695.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"e_1_3_3_29_1","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard JP","year":"1997","unstructured":"Leonard JP, , Sherman ML, , Fisher GL, , Buchanan LJ, , Larsen G, , Atkins MB, , Sosman JA, , Dutcher JP, , Vogelzang NJ, , Ryan JL. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood, 90(7):2541\u20132548.","journal-title":"Blood"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.4.12310"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.1.116"},{"issue":"13","key":"e_1_3_3_32_1","first-page":"3559","article-title":"Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12","volume":"60","author":"Mortarini R","year":"2000","unstructured":"Mortarini R, , Borri A, , Tragni G, , Bersani I, , Vegetti C, , Bajetta E, , Pilotti S, , Cerundolo V, , Anichini A. 2000. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res, 60(13):3559\u20133568.","journal-title":"Cancer Res"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999001750169934"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4672"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.4.1697"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.10"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.014"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05358"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.3.902.415k23_902_908"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.73"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-009-8100-2"},{"issue":"1","key":"e_1_3_3_42_1","first-page":"182","article-title":"Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo","volume":"54","author":"Tahara H","year":"1994","unstructured":"Tahara H, , Zeh HJ, , 3rd, Storkus WJ, , Pappo I, , Watkins SC, , Gubler U, , Wolf SF, , Robbins PD, , Lotze MT. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res, 54(1):182\u2013189.","journal-title":"Cancer Res"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.12.6466"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1357"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44562"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211316.15278.6e"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59806"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3637"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.313"}],"container-title":["Journal of Interferon &amp; Cytokine Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jir.2015.0049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2015.0049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2015.0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:17:29Z","timestamp":1781558249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jir.2015.0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1089\/jir.2015.0049"],"URL":"https:\/\/doi.org\/10.1089\/jir.2015.0049","relation":{},"ISSN":["1079-9907","1557-7465"],"issn-type":[{"value":"1079-9907","type":"print"},{"value":"1557-7465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,2]]}}}